Bragar Eagel & Squire reminds Erasca investors that the deadline to seek lead plaintiff appointment in a securities class action is August 10, 2026. The lawsuit, filed in the Southern District of California, covers purchasers of Erasca common stock between January 14, 2025 and April 26, 2026. It alleges that the company made false statements and failed to disclose that ERAS-0015 preclinical data relied on improper comparisons to Revolution Medicines, exposing Erasca to patent and trade secret violation risks. On April 28, 2026, Erasca disclosed a letter from Revolution Medicines alleging patent infringement and trade secret misappropriation, causing its share price to drop 48 percent from $19.15 to $9.90. Investors with losses can contact the firm at investigations@bespc.com or (212) 355-4648.
Erasca IncLawsuit alleges false statements and failure to disclose patent infringement risks, causing 48% stock drop.
Revolution Medicines Inc